Trial
NCT02366663
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Diffuse Large B-Cell Lymphoma
Intervention
90-Yttrium Ibritumomab tiuxetan
Why stopped
Withdrawal of sponsor support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-12